Sugi Predict

Sugi Predict / Compounds / SCHEMBL16634502

SCHEMBL16634502

SCHEMBL16634502

O=C(O)c1ncc(F)cc1Br

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HCAR2 Q8TDS4 3/20 0.42
▸ AGBL2 Q5U5Z8 1/20 0.40
▸ PKM P14618 1/20 0.39
▸ KDM4E B2RXH2 4/20 0.36
▸ ASPH Q12797 2/20 0.36
▸ KDM8 Q8N371 2/20 0.36
▸ ALDH1A1 P00352 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ PIN1 Q13526 1/20 0.34
▸ EGLN1 Q9GZT9 2/20 0.34
▸ SPR P35270 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ TTR P02766 1/20 0.33
▸ GPR17 Q13304 1/20 0.32
▸ HCAR1 Q9BXC0 1/20 0.31
▸ LDHA P00338 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22866557 0.82 AGBL2 (0.39) HCAR2AGBL2PKMALDH1A1SPR
SCHEMBL22854468 0.82 MAP2K1 (0.37) HCAR2AGBL2PKMKDM4ESPR
SCHEMBL29560615 0.82 AGBL2 (0.39) HCAR2AGBL2PKMALDH1A1SPR
SCHEMBL22854245 0.82 AGBL2 (0.35) HCAR2AGBL2PKMSPR
SCHEMBL4976345 0.79 ALDH1A1 (0.45) HCAR2PKMKDM4EALDH1A1POLB
SCHEMBL107357 0.79 HCAR2 (0.45) HCAR2AGBL2KDM4EASPHKDM8
SCHEMBL30960730 0.78 NPSR1 (0.41) AGBL2PKMKDM4EALDH1A1SMN1; SMN2
SCHEMBL16632434 0.78 NPSR1 (0.41) AGBL2PKMKDM4EALDH1A1SMN1; SMN2
SCHEMBL8566219 0.78 KDM4E (0.46) HCAR2AGBL2KDM4EASPHKDM8
SCHEMBL15991202 0.78 SPR (0.48) HCAR2AGBL2KDM4EASPHKDM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590089-B2 Processes for preparing toll-like receptor modulator compounds GILEAD SCIENCES, INC. (US) 2026-03-31 — — US disclosed
US-20260028352-A1 MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF SUZHOU LANGRUI BIOPHARMACEUTICAL CO LTD (CN) 2026-01-29 — — US disclosed
EP-4635949-A1 SUBSTITUTED TETRAHYDROCYCLOPENTYL[C]PYRROLE DERIVATIVE, PREPARATION METHOD, INTERMEDIATE AND USE THEREOF Jiangsu NHWA Pharmaceutical Co., Ltd (CN) 2025-10-22 — — EP disclosed
EP-4598923-A1 SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS The Regents of the University of California (US) 2025-08-13 — — EP disclosed
EP-4585598-A1 MACROCYCLIC IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF Suzhou Langrui Biopharmaceutical Co., Ltd. (CN) 2025-07-16 — — EP disclosed
CN-119371422-A Methods for preparing Toll-like receptor modulator compounds 吉利德科学公司 2025-01-28 — — CN disclosed
CN-119119033-A Pyrazolopyridone compounds 百济神州有限公司 2024-12-13 — — CN disclosed
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 — — US disclosed
US-20240352037-A1 HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS NUVALENT, INC. 2024-10-24 — — US disclosed
CN-114269744-B Methods for preparing Toll-like receptor modulator compounds 吉利德科学公司 2024-10-18 — — CN disclosed
US-10239863-B2 Factor XIa inhibitors MERCK SHARP & DOHME CORP. (US) 2019-03-26 — — US disclosed
US-20180179180-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2018-06-28 — — US disclosed
US-20180179180-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2018-06-28 — — US disclosed
WO-2017178344-A1 NOVEL N-[(HETEROARYLOXY)PROPANYL]HETEROARYL CARBOXAMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2017-10-19 — — WO disclosed
US-20160257668-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2016-09-08 — — US disclosed
US-20160257668-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2016-09-08 — — US disclosed
US-20160257668-A1 Factor XIa Inhibitors MERCK SHARP & DOHME CORP. (US) 2016-09-08 — — US disclosed
EP-3054944-A1 FACTOR XIa INHIBITORS Merck Sharp & Dohme Corp. (US) 2016-08-17 — — EP disclosed
WO-2015054087-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 — — WO disclosed
WO-2015054087-A1 FACTOR XIa INHIBITORS MERCK SHARP & DOHME CORP. (US) 2015-04-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 HCAR2 35/4885AGBL2 2833/4885PKM 4125/4885
US-12590089-B2 Processes for preparing toll-like receptor modulator compounds TLR8, MYD88, TLR6 HCAR2 591/4885AGBL2 1864/4885PKM 1105/4885
US-20180179180-A1 Factor XIa Inhibitors F11, SERPINC1, TFPI HCAR2 1833/4885AGBL2 1107/4885PKM 922/4885
US-20160257668-A1 Factor XIa Inhibitors F11, SERPINC1, TFPI HCAR2 1833/4885AGBL2 1107/4885PKM 922/4885
US-20260028352-A1 MACROCYCLIC IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF WEE2, WEE1, ROR1 HCAR2 1416/4885AGBL2 2883/4885PKM 491/4885
US-20240352037-A1 HETEROAROMATIC MACROCYCLIC ETHER CHEMOTHERAPEUTIC AGENTS ABCB1, CYP2C8, PAICS HCAR2 2427/4885AGBL2 3037/4885PKM 2466/4885
US-10239863-B2 Factor XIa inhibitors F11, SERPINC1, TFPI HCAR2 1833/4885AGBL2 1107/4885PKM 922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.